Bayer's Kogenate approved for paediatric prophylaxis in haemophilia
This article was originally published in Scrip
Bayer HealthCare's Kogenate FS (sucrose formulated recombinant Factor VIII) has received US FDA approval for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children aged 0-16 years with severe haemophilia A with no pre-existing joint damage.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.